Grafalon

Grafalon is an injectable solution containing the active ingredient Anti‑T Lymphocyte Immunoglobulin for Human Use, Rabbit. It is supplied without a specified strength and is administered intravenously under prescription. As a rabbit-derived anti‑thymocyte globulin, Grafalon belongs to the immunosuppressant class and is used in clinical settings to modulate T‑cell activity in transplant patients. The product is marketed in the European Union and is classified under ATC code L04AA02.

Grafalon is indicated for specific immunosuppressive purposes in transplant medicine.

- Prevention of acute graft‑versus‑host disease (GVHD) following allogeneic hematopoietic stem cell transplantation. - Induction of immunosuppression to reduce the risk of acute rejection in solid organ transplantation, such as kidney, liver, or heart grafts. - Adjunct therapy in conditioning regimens for bone marrow transplantation to facilitate engraftment. - Use as part of a prophylactic immunosuppressive protocol in patients receiving high‑risk transplants.

The safety profile of Grafalon includes a range of observed adverse reactions, which are categorized by frequency and clinical significance.

Common: - Fever, chills, or rigors during infusion. - Nausea, vomiting, or mild gastrointestinal upset. - Transient lymphopenia with reduced T‑cell counts.

Serious: - Severe infusion reactions including anaphylaxis or bronchospasm. - Cytokine release syndrome with high fever and hypotension. - Opportunistic infections such as viral, fungal, or bacterial due to profound immunosuppression.

Clinicians should consider several precautionary measures when prescribing Grafalon to minimize risks and ensure appropriate patient monitoring.

- Assess baseline complete blood count and renal function before initiation. - Monitor vital signs and temperature closely during and after each infusion. - Screen for active infections, including viral hepatitis and HIV, prior to treatment. - Use pre‑medication (e.g., antihistamines, corticosteroids) to reduce infusion‑related reactions. - Adjust dose or discontinue therapy in patients with severe hypersensitivity or uncontrolled infections.

Grafalon may interact with other medications, influencing its efficacy or safety profile.

Avoid: - Concurrent use with live vaccines due to heightened risk of infection. - Simultaneous administration of other potent T‑cell depleting agents without specialist guidance.

Use with caution: - Combine with nephrotoxic drugs such as calcineurin inhibitors; monitor renal function. - Co‑administer antiviral agents that require dose adjustment in immunosuppressed patients. - Monitor blood glucose closely if combined with corticosteroids, as hyperglycemia risk may increase.